Inter-individual variation of inflammatory markers of cardiovascular risks and diseases

被引:16
作者
Berrahmoune, H
Lamont, J
Fitzgerald, P
Visvikis-Siest, S
机构
[1] Univ Nancy 1, Fac Pharm, INSERM, U525 Equipe 4, F-54000 Nancy, France
[2] Randox Ltd, Crumlin, Antrim, North Ireland
关键词
atherosclerosis; environmental factors; intermediate phenotypes of inflammation; polymorphisms;
D O I
10.1515/CCLM.2005.116
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Cardiovascular diseases are a real public health problem and have multifactorial origin. Full comprehension of these diseases is very difficult because of their clinical and biological heterogeneity. The best way to understand the development of these diseases is to first investigate each biological system involved in the diseases and secondly, interactions between them. Studying intermediate phenotype variation for these biological systems is a new and promising approach for their elucidation. Among these metabolic systems, inflammation is known to be implicated in the occurrence and worsening of cardiovascular diseases. For this review, we chose to report the most important results concerning environmental, genetic and epigenetic determinants that influence intermediate phenotypes (protein and RNA levels) of inflammation. Indeed, numerous studies have investigated these determinants in healthy populations, in other words, without the influence of either disease or medication. This new approach will help to better understand the regulation of these intermediate phenotypes and to identify a panel of risk markers, which may be useful in predicting and warning those at risk and in giving adequate treatment to each patient.
引用
收藏
页码:671 / 684
页数:14
相关论文
共 112 条
[1]   Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies [J].
Andreotti, F ;
Porto, I ;
Crea, F ;
Maseri, A .
HEART, 2002, 87 (02) :107-112
[2]  
Arias Julia, 2003, Invest. clín, V44, P41
[3]  
Auer Johann, 2003, Am J Pharmacogenomics, V3, P317, DOI 10.2165/00129785-200303050-00003
[4]   IMMUNOSUPPRESSIVE THERAPY OF AUTOIMMUNE-DISEASES (REPRINTED FROM TRENDS IN PHARMACOLOGICAL SCIENCES, VOL 14, PG 213-217, 1993) [J].
BACH, JF .
IMMUNOLOGY TODAY, 1993, 14 (06) :322-326
[5]   An intronic polymorphic repeat sequence modulates interleukin-1 alpha gene regulation [J].
Bailly, S ;
Israel, N ;
Fay, M ;
GougerotPocidalo, MA ;
Duff, GW .
MOLECULAR IMMUNOLOGY, 1996, 33 (11-12) :999-1006
[6]   Circulating interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha, and soluble ICAM-1 in patients with chronic stable angina and myocardial infarction [J].
Balbay, Y ;
Tikiz, H ;
Baptiste, RJ ;
Ayaz, S ;
Sasmaz, H ;
Korkmaz, S .
ANGIOLOGY, 2001, 52 (02) :109-114
[7]   Analysis of allelic expression patterns of IL-2, IL-3 IL-4, and IL-13 in human CD4+ T cell clones [J].
Bayley, JP ;
Bakker, AM ;
Kaijzel, EL ;
Wierenga, EA ;
van der Pouw-Kraan, TCTM ;
Huizinga, TWJ ;
Verweij, CL .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (08) :2142-2148
[8]   Functional analysis of linker-scan mutants spanning the-376-308,-244, and-238 polymorphic sites of the TNF-α promoter [J].
Bayley, JP ;
de Rooij, H ;
van den Elsen, PJ ;
Huizinga, TWJ ;
Verweij, CL .
CYTOKINE, 2001, 14 (06) :316-323
[9]   Allele-specific expression of the IL-1α gene in human CD4+ T cell clones [J].
Bayley, JP ;
van Rietschoten, JGI ;
Bakker, AM ;
van Baarsen, L ;
Kaijzel, EL ;
Wierenga, EA ;
Kraan, TCTMV ;
Huizinga, TWJ ;
Verweij, CL .
JOURNAL OF IMMUNOLOGY, 2003, 171 (05) :2349-2353
[10]   Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women [J].
Bermudez, EA ;
Rifai, N ;
Buring, J ;
Manson, JE ;
Ridker, PA .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (10) :1668-1673